Biotechnology major Biocon on Wednesday said it has entered into a settlement with Celgene Corporation regarding patents for Revlimid, a medication used to treat bone marrow cancer.
The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide), the Bengaluru-based company said in a regulatory filing.
It did not share details of the agreement.
Celgene had filed a complaint in the US, against Biocon for potential patent infringement.
Biocon shares were trading 0.45 per cent up at ₹358.30 apiece on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.